FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126154946> ?p ?o ?g. }

• W3126154946 endingPage "30" @default.
• W3126154946 startingPage "30" @default.
• W3126154946 abstract "A variety of new sources describing community pharmacy-based take-home naloxone (THN) programs have emerged recently in the literature. There is a need to define the types of take-home naloxone programs being offered to support future research designs in implementing and evaluating standardized programs that fill pharmacist and patient knowledge gaps and lift current barriers for optimal community pharmacy naloxone provision. The objective of this paper is to summarize the literature on community pharmacy-based THN programs, including specific program interventions used to increase naloxone dispensing, naloxone availability and dispensing patterns, facilitators and barriers for the THN programs, and knowledge gaps. Online databases such as PubMed, EMBASE, Scopus, and International Pharmaceutical Abstracts (IPA) and a search of the grey literature were used to identify eligible sources. Sources were screened by two reviewers for eligibility in COVIDENCE software. Both reviewers compared screening results and resolved conflicts through discussion. A data extraction form for all identified full texts was completed by both reviewers and results were compiled through reviewer discussion. Fifty-two sources met the eligibility criteria. The top three barriers identified were: cost/coverage of naloxone, stigma, and education/training for pharmacists. THN program interventions included screening tools, checklists, pocket cards, patient brochures, and utilizing the pharmacy management system to flag eligible patients. Patient knowledge gaps included naloxone misinformation and lack of awareness, while pharmacists demonstrated administrative, clinical, and counselling knowledge gaps. Naloxone availability was found to be highly variable, where independent and rural pharmacies were less likely to stock or dispense naloxone. Further, pharmacies located in districts with higher rates of opioid overdose deaths and lower household income were also less likely to have naloxone available. This review identified multiple new programs, showcasing that the implementation and evaluation of THN programs are an expanding area of research. Future research should focus on implementing and evaluating a THN program through a randomized controlled trial design that incorporates solutions for the barriers and knowledge gaps identified in this study." @default.
• W3126154946 created "2021-02-15" @default.
• W3126154946 creator A5012854083 @default.
• W3126154946 creator A5016307184 @default.
• W3126154946 creator A5058146592 @default.
• W3126154946 creator A5062190270 @default.
• W3126154946 date "2021-02-02" @default.
• W3126154946 modified "2023-10-01" @default.
• W3126154946 title "What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review" @default.
• W3126154946 cites W1968086599 @default.
• W3126154946 cites W2023896204 @default.
• W3126154946 cites W2075950485 @default.
• W3126154946 cites W2154373338 @default.
• W3126154946 cites W2283934245 @default.
• W3126154946 cites W2405640947 @default.
• W3126154946 cites W2585540506 @default.
• W3126154946 cites W2585652778 @default.
• W3126154946 cites W2587995871 @default.
• W3126154946 cites W2588406005 @default.
• W3126154946 cites W2592402598 @default.
• W3126154946 cites W2731283307 @default.
• W3126154946 cites W2766833490 @default.
• W3126154946 cites W2767566001 @default.
• W3126154946 cites W2767972279 @default.
• W3126154946 cites W2778794778 @default.
• W3126154946 cites W2795788666 @default.
• W3126154946 cites W2801514601 @default.
• W3126154946 cites W2801991165 @default.
• W3126154946 cites W2808092861 @default.
• W3126154946 cites W2850681858 @default.
• W3126154946 cites W2899813609 @default.
• W3126154946 cites W2906950346 @default.
• W3126154946 cites W2911642310 @default.
• W3126154946 cites W2918077387 @default.
• W3126154946 cites W2943995561 @default.
• W3126154946 cites W2944064629 @default.
• W3126154946 cites W2944689007 @default.
• W3126154946 cites W2948673540 @default.
• W3126154946 cites W2950942265 @default.
• W3126154946 cites W2956171214 @default.
• W3126154946 cites W2966409306 @default.
• W3126154946 cites W2968104968 @default.
• W3126154946 cites W2972560819 @default.
• W3126154946 cites W2974005807 @default.
• W3126154946 cites W2980951331 @default.
• W3126154946 cites W2982725428 @default.
• W3126154946 cites W2989306462 @default.
• W3126154946 cites W2990569977 @default.
• W3126154946 cites W2991208813 @default.
• W3126154946 cites W2993739234 @default.
• W3126154946 cites W3000413805 @default.
• W3126154946 cites W3003198501 @default.
• W3126154946 cites W3003392986 @default.
• W3126154946 cites W3004307250 @default.
• W3126154946 cites W3005618439 @default.
• W3126154946 cites W3006231633 @default.
• W3126154946 cites W3007242453 @default.
• W3126154946 cites W3007632455 @default.
• W3126154946 cites W3012834857 @default.
• W3126154946 cites W3017269474 @default.
• W3126154946 cites W3164384625 @default.
• W3126154946 cites W4230777604 @default.
• W3126154946 cites W4249750715 @default.
• W3126154946 cites W4289455509 @default.
• W3126154946 cites W4294215472 @default.
• W3126154946 doi "https://doi.org/10.3390/pharmacy9010030" @default.
• W3126154946 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7931101" @default.
• W3126154946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33540676" @default.
• W3126154946 hasPublicationYear "2021" @default.
• W3126154946 type Work @default.
• W3126154946 sameAs 3126154946 @default.
• W3126154946 citedByCount "19" @default.
• W3126154946 countsByYear W31261549462021 @default.
• W3126154946 countsByYear W31261549462022 @default.
• W3126154946 countsByYear W31261549462023 @default.
• W3126154946 crossrefType "journal-article" @default.
• W3126154946 hasAuthorship W3126154946A5012854083 @default.
• W3126154946 hasAuthorship W3126154946A5016307184 @default.
• W3126154946 hasAuthorship W3126154946A5058146592 @default.
• W3126154946 hasAuthorship W3126154946A5062190270 @default.
• W3126154946 hasBestOaLocation W31261549461 @default.
• W3126154946 hasConcept C104863432 @default.
• W3126154946 hasConcept C126322002 @default.
• W3126154946 hasConcept C15744967 @default.
• W3126154946 hasConcept C159110408 @default.
• W3126154946 hasConcept C170493617 @default.
• W3126154946 hasConcept C27415008 @default.
• W3126154946 hasConcept C2778750930 @default.
• W3126154946 hasConcept C2779457091 @default.
• W3126154946 hasConcept C2781063702 @default.
• W3126154946 hasConcept C509550671 @default.
• W3126154946 hasConcept C512399662 @default.
• W3126154946 hasConcept C71924100 @default.
• W3126154946 hasConceptScore W3126154946C104863432 @default.
• W3126154946 hasConceptScore W3126154946C126322002 @default.
• W3126154946 hasConceptScore W3126154946C15744967 @default.
• W3126154946 hasConceptScore W3126154946C159110408 @default.
• W3126154946 hasConceptScore W3126154946C170493617 @default.

• next